A revolutionary new test for the early detection of testicular cancer—the most common cancer among young men—is now available in the UK. Developed by Cambridge-based EDX Medical, the non-invasive “TC100” test boasts exceptional accuracy across all age groups and ethnicities. It also delivers 100% sensitivity in detecting cancer recurrence during post-treatment monitoring and long-term surveillance of survivors.
With approximately 2,500 new cases of testicular cancer diagnosed annually in the UK and around 50,000 survivors, the launch of this test offers hope to many men in need of accurate and reliable monitoring.
The TC100 test requires only a simple blood sample, which can be easily taken by a healthcare professional and sent to EDX Medical’s lab for analysis. Using an AI-powered algorithm, the test analyses multiple tumour biomarkers—including the novel M371 micro-RNA biomarker alongside the standard serum markers AFP (Alpha-fetoprotein), HCG (Human Chorionic Gonadotrophin), and LDH (Lactate Dehydrogenase). The results are compiled into a comprehensive clinical report to support diagnosis and treatment decisions.
This innovative test delivers up to 99% sensitivity and 96% specificity for initial diagnosis, and 100% sensitivity in monitoring for recurrence. It integrates seamlessly with the current NHS testicular cancer pathway by reporting on the standard biomarkers already in use, enhancing accessibility and clinical utility.
The test’s development is backed by over 30 clinical studies, confirming its effectiveness for early diagnosis, detection of metastatic disease, and recurrence of both seminoma and non-seminoma forms of testicular cancer.
Professor Sir Chris Evans, OBE, founder of EDX Medical Group plc, commented:
“Testicular cancer is a terrifying prospect for many young men, and there has long been a lack of awareness and hesitance around getting checked. We’re proud to launch the most advanced test ever developed. With boys as young as 15 at risk, this test offers reassurance and could be a lifesaving tool for those undergoing regular monitoring after diagnosis.”
Prominent public figures who have battled testicular cancer—such as actor Jack James Ryan, radio presenter Chris Stark, and former Welsh international footballer John Hartson—continue to raise awareness and advocate for early detection.
Jack James Ryan, a campaigner with the Teenage Cancer Trust, said:
“There’s still a huge stigma around testicular cancer, especially when it comes to physical examinations. A blood test that offers a highly accurate result without the awkwardness of a physical check will encourage more men to get tested sooner. This is a game changer.”
Dr Karen Robb, Director of Programme Implementation for Cancer at leading men’s health charity Movember, added:
“This test is a major step forward in early diagnosis. During Testicular Cancer Awareness Month, we’re reminding young men to ‘Know Thy Nuts’—get familiar with your body and speak up if something doesn’t feel right. Awareness and early detection save lives.”
Renowned Michelin-starred chef Andreas Antona, who was diagnosed with testicular cancer in 2012, believes this test will be life-changing:
“Looking back, early detection would have made a huge difference. This kind of testing not only saves lives but also offers peace of mind for those worried about recurrence.”
Dr Mike Hudson, CEO of EDX Medical, emphasized the broader impact:
“The TC100 test allows doctors to detect cancer earlier, reduce the need for unnecessary scans and treatments, and improve overall quality of life for patients. It’s a powerful new tool in the fight against testicular cancer.”
The TC100 test will be available to both private and public healthcare providers in the coming weeks, marking a significant advancement in cancer diagnostics during Testicular Cancer Awareness Month.
About EDX Medical Group
EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.
EDX Medical conducts product development, validation and distribution to ISO 13485 and provides PCR and genomic sequencing services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).
